Sotera Health Intrinsic Value Calculation – Sotera Health: Uncertainty Looms Over Stock Performance
June 18, 2023
🌧️Trending News
Sotera Health ($NASDAQ:SHC) is a health sciences company that is poised to revolutionize the way healthcare is delivered. Despite the potential of this innovative organization, there are still many unknowns when it comes to investing in their stock. Investors must consider the risks of investing in a company that is still in its early stages, and whose success is not yet guaranteed. Moreover, there is no guarantee as to the direction of the stock price, and its performance may be significantly impacted by factors outside of Sotera Health’s control. Investors must also take into account the potential for Sotera Health’s stock to be volatile, as unexpected news or market events can quickly cause prices to fluctuate.
Additionally, the liquidity and trading volume of Sotera Health’s stock may be limited, which could make it difficult for investors to sell their holdings at a desirable price. As a result, investors should be aware of the risks and uncertainties surrounding Sotera Health’s stock before making any investments.
Share Price
Tuesday was a positive day for SOTERA HEALTH stock as it opened at $14.7 and closed at $15.0, up by 2.0% from their closing price the previous day. This comes as a surprise to many, as there is a great deal of uncertainty surrounding the stock in the current market. There were some analysts that predicted the stock would see a decline but the performance on Tuesday proved them wrong.
Investors have been closely tracking the stock as it could signify a shift in the current market conditions. While the future of the stock remains to be seen, the positive performance on Tuesday is a testament to the potential of SOTERA HEALTH in the current market. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Sotera Health. More…
| Total Revenues | Net Income | Net Margin |
| 987.52 | -261.37 | 12.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sotera Health. More…
| Operations | Investing | Financing |
| 261.87 | -191.38 | 472.13 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sotera Health. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.41k | 3.05k | 1.24 |
Key Ratios Snapshot
Some of the financial key ratios for Sotera Health are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 8.8% | 9.5% | -18.7% |
| FCF Margin | ROE | ROA |
| 7.1% | -32.9% | -3.4% |
Analysis – Sotera Health Intrinsic Value Calculation
At GoodWhale, we have conducted an analysis of SOTERA HEALTH‘s fundamentals. Our proprietary Valuation Line has calculated the intrinsic value of SOTERA HEALTH share to be around $21.5. This means that the stock is currently trading at $15.0, which is a 30.3% undervaluation. Investors should consider buying the stock to take advantage of the current undervalued price before it returns to an accurately priced level. More…
Peers
The company has a strong presence in the United States, Europe, and Asia. Pharmigene Inc, Inotiv Inc, and Centogene NV are all major competitors of Sotera Health Co.
– Pharmigene Inc ($TPEX:7595)
Pharmigene Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for the treatment of cancer and other diseases. The company’s lead product candidate is PG-301, a precision cancer medicine targeting the EZH2 protein. Pharmigene is also developing PG-201, a precision medicine targeting the KRAS protein, and PG-102, a precision medicine targeting the BRAF protein.
Pharmigene’s market cap is $658.49 million as of 2022. The company’s return on equity is -6.26%.
Pharmigene’s lead product candidate, PG-301, is a precision cancer medicine targeting the EZH2 protein. The company is also developing PG-201, a precision medicine targeting the KRAS protein, and PG-102, a precision medicine targeting the BRAF protein.
– Inotiv Inc ($NASDAQ:NOTV)
Inotiv Inc is a biotechnology company that focuses on the discovery and development of innovative therapies to treat patients with cancer and other serious diseases. The company’s market cap is $486.81M as of 2022, and its ROE is -6.96%. Inotiv’s products are designed to target the underlying cause of disease and improve patient outcomes. The company’s lead product candidates are in clinical trials for the treatment of solid tumors and blood cancers. Inotiv is headquartered in San Diego, California.
– Centogene NV ($NASDAQ:CNTG)
As of 2022, Centogene NV has a market cap of 28.16M. The company’s return on equity is -141.43%. Centogene NV is a biotechnology company that focuses on the diagnosis, treatment, and prevention of rare diseases. The company was founded in 2002 and is headquartered in Rostock, Germany.
Summary
Sotera Health is an innovator in the health and life science space, offering solutions to support laboratory and healthcare organizations. Sotera Health is a publicly traded company on the New York Stock Exchange. The current stock valuation of Sotera Health has been relatively steady, but there are still many uncertainties surrounding the stock.
Analysts are watching closely to see if Sotera Health can continue to increase its revenue, build a more diverse portfolio of products and services, and capitalize on industry trends. Investors should pay close attention to any potential news and developments regarding Sotera Health to ensure their investment strategies remain up-to-date.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
